Related Experiment Video
Updated: Jun 14, 2025
09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
290
Social Vulnerability and National Diabetes Prevention Program Recognition Status
Taynara Formagini1, Daphnee Rodriguez2, Ariba Rezwan3
1Department of Family Medicine, University of California San Diego, San Diego, California; School of Social Work, University of Central Florida, Orlando, Florida.
American Journal of Preventive Medicine
|September 1, 2024
Summary
Counties with higher social vulnerability face greater odds of having no organizations with full recognition in the National Diabetes Prevention Program (National DPP). This highlights disparities that need addressing for program equity and sustainability.
Area of Science:
- Public Health
- Health Disparities
- Diabetes Prevention
Background:
- The National Diabetes Prevention Program (National DPP) aims to reduce type 2 diabetes incidence in the U.S.
- Organizations require full/full-plus recognition for program sustainability and reimbursement.
- Disadvantaged areas may face barriers to achieving full recognition.
Purpose of the Study:
- To examine the association between county-level social vulnerability and National DPP full/full-plus recognition status.
- To identify potential disparities in program recognition based on social vulnerability.
Main Methods:
- Utilized the 2022 National DPP registry and 2018 CDC Social Vulnerability Index (SVI).
- Created a three-level categorical variable for county recognition status (n=843).
- Employed a multinomial logit model to analyze the association between SVI and recognition, adjusting for confounders.
Main Results:
- Higher social vulnerability was significantly associated with a greater likelihood of having no organizations with full/full-plus recognition.
- Counties with high SVI had 2.63 times higher odds of having no fully recognized organizations compared to those with all fully recognized organizations.
Conclusions:
- Findings indicate disparities in National DPP recognition status in vulnerable communities.
- Strategies are needed to support organizations in high SVI areas to achieve full recognition.
- Addressing these disparities is crucial for program sustainability and reducing diabetes health inequities.
Related Concept Videos
01:15Diabetes: Symptoms, Diagnosis, and Complications
520
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:22Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
01:20Pathophysiology of Diabetes
908
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
908
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178